Search details
1.
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence.
J Cell Physiol
; 235(11): 7900-7910, 2020 11.
Article
in English
| MEDLINE | ID: mdl-31943171
2.
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.
J Cell Physiol
; 234(6): 7708-7717, 2019 06.
Article
in English
| MEDLINE | ID: mdl-30536609
3.
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy.
NPJ Breast Cancer
; 7(1): 47, 2021 May 05.
Article
in English
| MEDLINE | ID: mdl-33953182
4.
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.
Cancer Biol Ther
; 20(2): 192-200, 2019.
Article
in English
| MEDLINE | ID: mdl-30403909
5.
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study.
Sci Rep
; 7(1): 10597, 2017 09 06.
Article
in English
| MEDLINE | ID: mdl-28878375
6.
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience.
Oncotarget
; 8(34): 56921-56931, 2017 08 22.
Article
in English
| MEDLINE | ID: mdl-28915642
7.
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.
Oncotarget
; 7(14): 17932-44, 2016 Apr 05.
Article
in English
| MEDLINE | ID: mdl-26910921
Results
1 -
7
de 7
1
Next >
>>